Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

Company Overview

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies.

Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.

Key Stats

• Today's Range: $23.27 to $24.02
• 50-Day Range: $23.66 to $28.78
• 52-Week Range: $16.21 to $31.77
• Volume: 1.62 million shs
• Average Volume: 1.66 million shs
• Market Capitalization: $3.00 billion
• P/E Ratio: 113.81
• Dividend Yield: N/A
• Price Target: $35.57
• Consensus Rating: Moderate Buy

Arcutis Biotherapeutics Stock Analysis - MarketRank™

Arcutis Biotherapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 154th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Arcutis Biotherapeutics has a consensus price target of $35.57, representing about 48.8% upside from its current price of $23.90.

Amount of Analyst Coverage

Arcutis Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 185.00%

Earnings Growth

Earnings for Arcutis Biotherapeutics are expected to grow by 185.00% in the coming year, from $0.40 to $1.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcutis Biotherapeutics is 113.81, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcutis Biotherapeutics is 113.81, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.54.

Price to Book Value per Share Ratio

Arcutis Biotherapeutics has a P/B Ratio of 13.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.92% of the float of Arcutis Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.04.

Change versus previous month

Short interest in Arcutis Biotherapeutics has recently increased by 16.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcutis Biotherapeutics does not currently pay a dividend.

Dividend Growth

Arcutis Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.26

News Sentiment

Arcutis Biotherapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Arcutis Biotherapeutics this week, compared to 7 articles on an average week.

Search Interest

5 people have searched for ARQT on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,910,959.00 in company stock.

Percentage Held by Insiders

9.40% of the stock of Arcutis Biotherapeutics is held by insiders.

Percentage Held by Institutions

Arcutis Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/05/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ARQT
• CIK: 1787306
• Web: www.arcutis.com
• Phone: 805-418-5006
• Fax: N/A
• Employees: 150
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Arcutis Biotherapeutics: $35.57
• High Price Target: $40.00
• Low Price Target: $29.00
• Potential Upside/Downside: +48.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.21
• Trailing P/E Ratio: 113.81
• Forward P/E Ratio: 59.75
• P/E Growth: N/A
• Net Income: -$16.14 million
• Net Margins: 6.15%
• Pretax Margin: 6.31%
• Return on Equity: 15.05%
• Return on Assets: 6.51%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 2.92
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $376.07 million
• Price / Sales: 7.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.75 per share
• Price / Book: 13.66

Miscellaneous

• Outstanding Shares: 125,690,000
• Free Float: 113,877,000
• Market Cap: $3.00 billion
• Optionable: Optionable
• Beta: 1.50